Monday, September 7, 2026

Back to today

From X

SLS · short

Sellas Life Sciences Group I

SELLAS Life Sciences Group faces a short case arguing that even a strong clinical outcome does not support its current valuation.

Publications we follow

Every publication on this site, hand-picked.

108 publications

Newsletters 91

X accounts we follow

Every account on this site, hand-picked.

68 accounts

Investor letters we follow

78 firms

Sectors

Ordered by how often our editor reaches for them.